Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
1.
Brain Res ; 1382: 259-65, 2011 Mar 25.
Article En | MEDLINE | ID: mdl-21241675

Pristanic acid (Prist) is accumulated in various peroxisomal disorders characterized by severe neurological dysfunction whose pathogenesis is poorly understood. Since oxidative damage has been demonstrated in brain of patients affected by neurodegenerative disorders, in the present work we investigated the in vitro effects of Prist on important parameters of oxidative stress in cerebral cortex from young rats. Prist significantly increased malondialdehyde levels, reflecting an increase of lipid peroxidation. This effect was totally prevented by the free radical scavenger melatonin, suggesting the involvement of reactive species. Prist also provoked protein oxidative damage, as determined by increased carbonyl formation and sulfhydryl oxidation. Otherwise, it did not alter nitric oxide production, indicating that nitrogen reactive species were not implicated in the lipid and oxidative damage provoked by Prist. Furthermore, the concentration of glutathione (GSH), the major brain non-enzymatic antioxidant defense, was significantly decreased by Prist and this decrease was fully prevented by melatonin and attenuated by α-tocopherol. It is therefore presumed that Prist elicits oxidative stress in the brain probably via reactive oxygen species formation and that this pathomechanism may possibly be involved in the brain damage found in patients affected by peroxisomal disorders where Prist accumulates.


Brain Chemistry/drug effects , Brain Damage, Chronic/chemically induced , Cerebral Cortex/drug effects , Fatty Acids/toxicity , Oxidative Stress/drug effects , Peroxisomal Disorders/chemically induced , Animals , Brain Chemistry/physiology , Brain Damage, Chronic/metabolism , Brain Damage, Chronic/physiopathology , Cerebral Cortex/growth & development , Cerebral Cortex/physiopathology , Disease Models, Animal , Fatty Acids/metabolism , Lipid Peroxidation/drug effects , Lipid Peroxidation/physiology , Male , Oxidative Stress/physiology , Peroxisomal Disorders/metabolism , Peroxisomal Disorders/physiopathology , Rats , Rats, Wistar
2.
Exp Neurol ; 210(2): 560-76, 2008 Apr.
Article En | MEDLINE | ID: mdl-18291369

Cerebral white matter injury during prenatal maternal infection characterized as periventricular leukomalacia is the main substrate for cerebral palsy (CP) in premature infants. Previously, we reported that maternal LPS exposure causes oligodendrocyte (OL)-injury/hypomyelination in the developing brain which can be attenuated by an antioxidant agent, N-acetyl cysteine (NAC). Herein, we elucidated the role of peroxisomes in LPS-induced neuroinflammation and cerebral white matter injury. Peroxisomes are important for detoxification of reactive oxidative species (ROS) and metabolism of myelin-lipids in OLs. Maternal LPS exposure induced selective depletion of developing OLs in the fetal brain which was associated with ROS generation, glutathione depletion and peroxisomal dysfunction. Likewise, hypomyelination in the postnatal brain was associated with decrease in peroxisomes and OLs after maternal LPS exposure. Conversely, NAC abolished these LPS-induced effects in the developing brain. CP brains imitated these observed changes in peroxisomal/myelin proteins in the postnatal brain after maternal LPS exposure. In vitro studies revealed that pro-inflammatory cytokines cause OL-injury via peroxisomal dysfunction and ROS generation. NAC or WY14643 (peroxisome proliferators activated receptor (PPAR)-alpha agonist) reverses these effects of pro-inflammatory cytokines in the wild-type OLs, but not in PPAR-alpha(-/-) OLs. Similarly treated B12 oligodenroglial cells co-transfected with PPAR-alpha siRNAs/pTK-PPREx3-Luc, and LPS exposed PPAR-alpha(-/-) pregnant mice treated with NAC or WY14643 further suggested that PPAR-alpha activity mediates NAC-induced protective effects. Collectively, these data provide unprecedented evidence that LPS-induced peroxisomal dysfunction exacerbates cerebral white matter injury and its attenuation by NAC via a PPAR-alpha dependent mechanism expands therapeutic avenues for CP and related demyelinating diseases.


Acetylcysteine/therapeutic use , Free Radical Scavengers/therapeutic use , Lipopolysaccharides/toxicity , Neuroglia/drug effects , Peroxisomal Disorders/chemically induced , Acyltransferases/metabolism , Analysis of Variance , Animals , Brain Injuries/chemically induced , Brain Injuries/pathology , Case-Control Studies , Cells, Cultured , Child, Preschool , Drug Interactions , Female , Fetus , Flow Cytometry/methods , Humans , In Vitro Techniques , Infant , Neuroglia/pathology , Peroxisomal Disorders/drug therapy , Peroxisomes/drug effects , Peroxisomes/metabolism , Pregnancy , Prenatal Exposure Delayed Effects , RNA, Small Interfering/metabolism , Reactive Oxygen Species , Time Factors , Transfection/methods
3.
Biochem Biophys Res Commun ; 343(1): 229-38, 2006 Apr 28.
Article En | MEDLINE | ID: mdl-16530726

Psychosine (galactosylsphingosine) accumulates in the brain of Krabbe disease (KD) patients as well as twitcher mice, a murine model of KD, resulting in loss of oligodendrocytes and myelin. This study documents progressive loss of peroxisomal proteins/functions and induction of expression of inflammatory cytokine TNF-alpha in twitcher brain. The observed decrease in peroxisomal proteins was accompanied by decreased level of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), one of the transcription factors required for expression of peroxisomal protein genes. The role of psychosine in down-regulation of PPAR-alpha activity was further supported by decreased PPAR-alpha mediated PPRE transcriptional activity in cells transfected with PPAR-alpha and PPRE reporters. The psychosine-induced down-regulation of PPAR activity and cell death was attenuated by sPLA2 inhibitor. Therefore, this study provides the first evidence of peroxisomal abnormality in a lysosomal disorder, suggesting that such dysfunction of peroxisomes may play a role in the pathogenesis of Krabbe disease.


Brain/enzymology , Leukodystrophy, Globoid Cell/enzymology , PPAR alpha/antagonists & inhibitors , Peroxisomal Disorders/enzymology , Peroxisomes/enzymology , Psychosine/metabolism , Alkyl and Aryl Transferases/analysis , Alkyl and Aryl Transferases/metabolism , Animals , Apoptosis/drug effects , Down-Regulation , Enzyme Inhibitors/pharmacology , Genes, Reporter , Group II Phospholipases A2 , Leukodystrophy, Globoid Cell/chemically induced , Mice , Mice, Inbred Strains , PPAR alpha/genetics , PPAR alpha/metabolism , Peroxisomal Disorders/chemically induced , Peroxisomes/drug effects , Phospholipases A/antagonists & inhibitors , Psychosine/toxicity , Tumor Necrosis Factor-alpha/metabolism
4.
Toxicol Sci ; 50(2): 195-205, 1999 Aug.
Article En | MEDLINE | ID: mdl-10478855

This study compared the levels of cell proliferation and peroxisome proliferation in rodent liver with tumor incidence, to provide more information on the relationship between these events following chronic exposure. Fischer 344 rats were treated with 0, 100, 500, 2500, or 12,500 ppm DEHP, and B6C3F1 mice were treated with 0, 100, 500, 1500, or 6000 ppm DEHP in the diet for up to 104 weeks. Additional groups of rats and mice received the highest concentration for 78 weeks and then the control diet for an additional 26 weeks (recovery groups). Animals were terminated at weeks 79 and 105 for histopathologic examination. Elevated palmitoyl CoA oxidation activity and higher liver-to-body weight ratios were observed for the 2500- and 12,500-ppm groups of rats, and for the 500-, 1500-, and 6000-ppm groups of mice at Week 105. No increase in palmitoyl CoA oxidation activity was evident in the recovery group, and relative liver weights were near control levels following recovery. No hepatic cell proliferation was detected at Weeks 79 or 105 in either species although preliminary data indicated that cell proliferation did occur within the first 13 weeks of exposure. A significantly higher incidence of hepatocellular tumors was only observed for the 2500- and 12,500-ppm group and its recovery group of rats, and for the 500-, 1500-, and 6000-ppm groups and the recovery group of mice. The tumor incidences were reduced for the recovery groups compared with the groups fed DEHP continuously for 104 weeks. The data indicate that high levels of peroxisome proliferation and hepatomegaly are associated with DEHP hepatocarcinogenesis in rodent liver, and that the tumorigenic process may be arrested by cessation of DEHP treatment, suggesting that extended treatment with DEHP acts to promote tumor growth.


Carcinogens/toxicity , Diethylhexyl Phthalate/toxicity , Hepatomegaly/chemically induced , Liver Neoplasms/chemically induced , Peroxisomal Disorders/chemically induced , Animals , Carcinogenicity Tests , Cell Division/drug effects , Dose-Response Relationship, Drug , Female , Male , Mice , Organ Size/drug effects , Oxidation-Reduction , Palmitoyl Coenzyme A/drug effects , Palmitoyl Coenzyme A/metabolism , Peroxisome Proliferators/toxicity , Peroxisomes/enzymology , Rats , Rats, Inbred F344 , Sex Factors , Survival Rate , Time Factors
5.
Toxicol Pathol ; 24(3): 265-72, 1996.
Article En | MEDLINE | ID: mdl-8736381

The hepatic tumorigenicity of CI-924 (5,5'-(1,1'-biphenyl)-2,5-diylbis(oxy)(2,2-dimethylpentanoic acid)), a hypolipidemic agent, was evaluated in 50 B6C3F1 mice/sex/dose given drug in the diet at 0, 5, 25, and 75 mg/kg/day for 2 yr. Peroxisomal and drugmetabolizing enzyme determinations, as well as ultrastructural evaluations, were conducted in subsets of these same groups, because drugs of this class cause peroxisome proliferation and hepatic tumors in rodents. CI-924 elicited dose-dependent increases in the incidence of hepatocellular adenomas and carcinomas in both sexes that were statistically significant at 75 mg/kg. Stereologic evaluation revealed significant increases in hepatocellular peroxisome volume ratio, due to increased numbers of peroxisomes, in females at all doses and males at 75 mg/kg. Peroxisomal enzyme activity measurements revealed no change in catalase, but dose-dependent increases in carnitine acetyltransferase and cyanide-insensitive beta-oxidation in both sexes. Peroxisome proliferation, determined biochemically or ultrastructurally, was twice as great in females compared to males. Total cytochrome P-450 was increased in both sexes given 75 mg/kg. There were dose-dependent decreases in glutathione S-transferase in males and increased glutathione peroxidase in both sexes at 25 and 75 mg/kg. In conclusion, this study demonstrated that while CI-924 induced hepatic tumors in male and female B6C3F1 mice the associated peroxisome proliferation, while moderate in females, was only weak in the males after 2 yr of exposure.


Gemfibrozil/analogs & derivatives , Hypolipidemic Agents/toxicity , Liver Neoplasms, Experimental/chemically induced , Peroxisomal Disorders/chemically induced , Adenoma/chemically induced , Adenoma/pathology , Adenoma/ultrastructure , Animals , Cytochrome P-450 Enzyme System/metabolism , Enzymes/blood , Female , Gemfibrozil/toxicity , Liver/pathology , Liver Neoplasms, Experimental/pathology , Liver Neoplasms, Experimental/ultrastructure , Male , Mice , Mice, Inbred Strains , Microscopy, Electron , Peroxisomal Disorders/pathology
...